|
1
|
Marsh RW, Alonxo M, Bajaj S, et al:
Comprehensive review of the diagnosis and treatment of biliary
tract cancer 2012. Part II: multidisciplinary management. J Surg
Oncol. 106:339–345. 2012. View Article : Google Scholar
|
|
2
|
Khan SA, Davidson BR, Goldin RD, et al:
Guidelines for the diagnosis and treatment of cholangiocarcinoma:
an update. Gut. 61:1657–1669. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Briggs CD, Neal CP, Mann CD, Steward WP,
Manson MM and Berry DP: Prognostic molecular markers in
cholangiocarcinoma: a systematic review. Eur J Cancer. 45:33–47.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Delprat B, Schaer D, Roy S, Wang J, Puel
JL and Geering K: FXYD6 is a novel regulator of Na, K-ATPase
expressed in the inner ear. J Biol Chem. 282:7450–7456. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhu ZL, Zhao ZR, Zhang Y, et al:
Expression and significance of FXYD-3 protein in gastric
adenocarcinoma. Dis Markers. 28:63–69. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kayed H, Kleeff J, Kolb A, et al: FXYD3 is
overexpressed in pancreatic ductal adenocarcinoma and influences
pancreatic cancer cell growth. Int J Cancer. 118:43–54. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang MW, Gu P, Zhang ZY, et al: FXYD3
expression in gliomas and its clinicopathological significance.
Oncol Res. 18:133–139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maehata Y, Hirahashi M, Aishima S, et al:
Significance of dysadherin and E-cadherin expression in
differentiated-type gastric carcinoma with submucosal invasion. Hum
Pathol. 42:558–567. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kadowaki K, Sugimoto K, Yamaguchi F, Song
T, Watanabe Y, Singh K and Tokuda M: Phosphohippolin expression in
the rat central nervous system. Brain Res Mol Brain Res.
125:105–112. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shiina N, Yamaguchi K and Tokunaga M:
RNG105 deficiency impairs the dendritic localization of mRNAs for
Na+/K+ ATPase subunit isoforms and leads to
the degeneration of neuronal networks. J Neurosci. 30:12816–12830.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Olstad OK, Gautvik VT, Reppe S, et al:
Molecular heterogeneity in human osteosarcoma demonstrated by
enriched mRNAs isolated by directional tag PCR subtraction cloning.
Anticancer Res. 23:2201–2216. 2003.
|
|
12
|
Xiao M, Zhou NX, Gao LJ, et al: A study on
expression of human gene fxyd6 in bile duct benign and malignant
tumors by RT-PCR. Chin J Bases Clin General Sur. 15:223–225.
2007.(In Chinese).
|
|
13
|
Liu J, Zhou N and Zhang X: A monoclonal
antibody against human FXYD6. Hybridoma (Larchmt). 30:487–490.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Geering K: FXYD proteins: new regulators
of Na-K-ATPase. Am J Physiol Renal PhysSiol. 290:F241–F250. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Saxena A, Chua TC, Chu FC and Morris DL:
Improved outcomes after aggressive surgical resection of hilar
cholangiocarcinoma: a critical analysis of recurrence and survival.
Am J Surg. 202:310–320. 2011. View Article : Google Scholar
|
|
16
|
Nakanuma Y, Sato Y, Harada K, Sasaki M, Xu
J and Ikeda H: Pathological classification of intrahepatic
cholangiocarcinoma based on a new concept. World J Hepatol.
2:419–427. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ito Y, Nakamura Y, Takahashi N, et al: A
genetic association study of the FXYD domain containing ion
transport regulator 6 (FXYD6) gene, encoding phosphohippolin, in
susceptibility to schizophrenia in a Japanese population. Neurosci
Lett. 438:70–75. 2008. View Article : Google Scholar
|
|
18
|
Iwata Y, Yamada K, Iwayama Y, et al:
Failure to confirm genetic association of the FXYD6 gene with
schizophrenia: the Japanese population and meta-analysis. Am J Med
Genet B Neuropsychiatr Genet. 153B:1221–1227. 2010.PubMed/NCBI
|
|
19
|
Zhong N, Zhang R, Qiu C, et al: A novel
replicated association between FXYD6 gene and schizophrenia.
Biochem Biophys Res Commun. 405:118–121. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shen FZ, Zhang BY, Feng YJ, et al: Current
research in perineural invasion of cholangiocarcinoma. J Exp Clin
Cancer Res. 29:242010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shindo Y, Morishita K, Kotake E, et al:
FXYD6, a Na, K-ATPase regulator, is expressed in type II taste
cells. Biosci Biotechnol Biochem. 75:1061–1066. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rajasekaran SA, Huynh TP, Wolle DG, et al:
Na, K-ATPase subunits as markers for epithelial-mesenchymal
transition in cancer and fibrosis. Mol Cancer Ther. 9:1515–1524.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tummala R, Wolle D, Barwe SP, Sampson VB,
Rajasekaran AK and Pendyala L: Expression of Na, K-ATPase-beta(1)
subunit increases uptake and sensitizes carcinoma cells to
oxaliplatin. Cancer Chemother Pharmacol. 64:1187–1194. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mijatovic T, Ingrassia L, Facchini V and
Kiss R: Na+/K+-ATPase alpha subunits as new
targets in anticancer therapy. Expert Opin Ther Targets.
12:1403–1417. 2008.
|
|
25
|
Seligson DB, Rajasekaran SA, Yu H, et al:
Na, K-adenosine triphosphatase alpha1-subunit predicts survival of
renal clear cell carcinoma. J Urol. 179:338–345. 2008. View Article : Google Scholar : PubMed/NCBI
|
